Nutrition - 500 Beiträge pro Seite

[Kostolanys Erbe]

Achtung beobachten!!!
Nach den Berichten der Diabeteskonferenz in Paris kann sich hier einiges tun!
Sind nach Bekanntgabe enorm explodiert.
Schaut aber selbst:

NXXI
890068

Kosto

[luto9]

Bin erstmal raus $,48 zu 1,43

Handel lohnt sich nur in Amiland

[MaxLubin]

#1 #2

was meint ihr, wie geht es weiter? 1$ sollte halten...

luto9 .. glückwünsch

[MaxLubin]

New Clinical Trial Adds to Body of Evidence Showing Chromium PicolinateLowers Blood Sugar in Insulin-Treated People with Poorly-Controlled Type 2Diabetes

ZWOLLE, Netherlands, Sep 4, 2003 /PRNewswire-FirstCall via COMTEX/ -- In a third study presented at last month`s prestigious International Diabetes Federation (IDF) Congress in Paris researchers from Isala Clinics and University Hospital Groningen, Netherlands showed that daily nutritional supplementation with 1,000 mcg of chromium as chromium picolinate significantly decreased blood sugar levels in insulin-treated people with poorly-controlled type 2 diabetes. Managing glucose levels is important for maintaining long-term health and reducing complications associated with diabetes. Two chromium picolinate research presentations showing similar effects on blood sugar levels by the University of Vermont College of Medicine and Nutrition 21, Inc. (Nasdaq: NXXI) were also presented at the IDF Congress.

"The use of chromium picolinate in this trial produced significant improvements in HbA1c levels and other clinical parameters. It will help us determine the right therapeutic doses of chromium picolinate for select patient populations," explained Sebastiaan T. Houweling, lead investigator, Department of Internal Medicine, Isala Clinics. "This is one of the first studies to test chromium picolinate supplementation exclusively on patients with insulin-treated, poorly-controlled type 2 diabetes. Larger clinical studies are necessary to further evaluate the results and to investigate if these effects can be confirmed not only within the treated group, but also placebo controlled."

In the Netherlands`s double-blind, placebo-controlled study, 52 subjects were randomly assigned to three groups, to receive placebo, 500 mcg or 1,000 mcg of chromium, as chromium picolinate, per day. After six months, the average HbA1c in the 1,000 mcg chromium treated group showed a statistically significant improvement (a decrease from 9.5% to 9.0%).

The Clinical Trial

All 52 subjects had elevated glycosylated hemoglobin (HbA1c) levels greater than 8%, despite insulin requirements of greater than or equal to 50 units per day. (HbA1c is a marker of long-term blood sugar control). Investigators also measured serum lipids, body mass index (BMI), blood pressure and insulin requirements. Significant improvements were found in the cholesterol/HDL ratio (-0.46 and -0.32 in the 500 mcg and 1,000 mcg chromium groups, respectively). Trends for improvements were found for triglyceride levels in both chromium groups. Other endpoints were not significantly different between all three groups at the end of the study.

Blood Sugar Control - The Key for People with Type 2 Diabetes

"This trial further contributes to clinical research indicating that 1,000 mcg of chromium as chromium picolinate can effectively decrease blood sugar levels to help reduce the complications associated with diabetes," explains James Komorowski, MS, VP of Technical Services and Scientific Affairs for Nutrition 21, USA, who also presented research at the IDF Congress. "For patients with type 2 diabetes who already receive insulin treatment, the potential to improve glucose control with a convenient nutritional therapy such as chromium picolinate is clinically important and cost effective."

Chromium is an essential mineral that is a co-factor of insulin. The Netherlands`s study is the fourth human clinical trial using 1,000 mcg of chromium showing significant effects in improving blood sugar levels in people with insulin resistance and diabetes. There are two large definitive clinical trials now underway in the United States to further evaluate the effects of 1,000 mcg of chromium (as Chromax(R) chromium picolinate) on blood sugar levels in people with type 2 diabetes or metabolic syndrome.

Diabetes is a chronic disease characterized by high blood sugar levels that affects 194 million people worldwide. Diabetes is the leading cause of blindness and visual impairment and the fourth main cause of death in adults in most developing countries. People with diabetes are two-to-four times more likely to develop cardiovascular disease (CVD).

About Nutrition 21

Nutrition 21 is a leading developer and provider of nutritional products, whose health benefits are substantiated by clinical research. The Company markets Chromax chromium picolinate, the leading brand of chromium, as well as other nutritional products for people with type 2 diabetes. Nutrition 21 holds 35 patents for nutrition products, 22 for chromium compounds and their uses. The Company holds U.S and international patent rights for the use of 1,000 mcg of chromium, as chromium picolinate, supplementation to treat type 2 diabetes. More information is available at www.nutrition21.com.

SOURCE Nutrition 21, Inc.


CONTACT: US - Sue Preziotti, [phone], or Stacey Antine,
[phone], both for Nutrition 21

[Kostolanys Erbe]

hi leute,

was meinen die experten zu den neuen meldungen von nutrition21?
könnten pharmagrößen wie pfizer, aventis, novartis etc. anklopfen?

über eure meinung würde ich mich sehr freuen

kosto

[Kostolanys Erbe]

National Institutes of Health - NIH - Funds Major Chromium Picolinate and Type 2 Diabetes Research Study
TUESDAY, SEPTEMBER 09, 2003 10:27 AM
- BusinessWire

PURCHASE, N.Y., Sep 9, 2003 (BUSINESS WIRE) -- The National Institutes of Health (NIH) awarded Dr. William Cefalu, at the prestigious Pennington Biomedical Research Center of Louisiana State University, a substantial research grant to evaluate the use of Chromax(R) chromium picolinate supplementation in people with type 2 diabetes. This landmark study will make a critical contribution to the existing body of clinical evidence demonstrating the importance of chromium picolinate in the management of diabetes, a disease that affects 194 million people worldwide.

Dr. Cefalu states, "This study will use `gold standard` techniques to evaluate carbohydrate metabolism in human subjects with type 2 diabetes and will also use techniques to evaluate the specific mechanism by which it may work. Based on the large numbers of subjects to be evaluated, this study has the potential to specifically address the role of chromium picolinate in diabetes, and follow-up on the positive observations seen in the obese animal models." There are currently 13 published human clinical studies demonstrating significant efficacy with chromium picolinate supplementation in diabetes and metabolic syndrome.

Nutrition 21`s (NXXI) Chromax chromium picolinate has been selected as the form of chromium for this landmark study. Gail Montgomery, President and CEO, Nutrition 21, Inc. comments, "This is great news for millions of people with diabetes who can potentially benefit from chromium picolinate supplementation as a low cost, safe, and effective nutritional therapy. The significant investment by the NIH in chromium picolinate research complements and is expected to further validate our own aggressive research and development program. In keeping with Nutrition 21`s business strategy, we expect government participation to help facilitate our near-term objective of securing Food and Drug Administration (FDA) approved health claims for our products. More importantly, this should accelerate the ultimate goal of having Nutrition 21`s proprietary chromium technologies, like Diachrome(R), incorporated as standard health plan treatment protocol for people with diabetes.

Nutrition 21 is a leading developer and provider of nutritional products, whose health benefits are substantiated by clinical research. The Company markets Chromax chromium picolinate, the leading brand of chromium, and holds 35 patents for nutrition products, 22 for chromium compounds and their uses. More information is available at www.nutrition21.com More information about Chromax is available at www.chromax.com. and Diachrome at www.diachrome.com


kosto

[luto9]

BREAKDOWN WATCH for possible breakdown below 1.01, no support in area just below.
Type: Continuation breakdown from single support.
Target: 0.87, -14.7% Cover: 1.1, Loss: 7.8%, Profit/Loss ratio: 1.9 : 1 - Fair


Habe eine Kauforder für $,90
bin mal gespannt

[Kostolanys Erbe]

Freitag + 9%



kosto